2025 MPS MasterClass
The Muenzer MPS Research & Treatment Center hosted the 2025 MPS MasterClass virtually on November 13–14, 2025, from 8:00 AM to 5:00 PM EST. This two-day program was delivered via Zoom Webinar, and session recordings are now available on demand through the UNC Health YouTube channel and the MPS Center website.
The MasterClass was designed for clinicians, researchers, and allied health professionals involved in the care of individuals with Mucopolysaccharidosis (MPS). Sessions featured expert faculty and addressed key topics in diagnosis, management, and emerging therapies, with opportunities to earn continuing education credit. While the content was primarily geared toward medical professionals and learners, family members and individuals affected by MPS were also welcome to attend.
Eligible continuing education for Physicians, Nurse Practitioners, and Physician Assistants.
Completion of the Post MPS MasterClass Credit Survey is required for participants seeking continuing education credit. Participants who are not seeking credit are also welcome to complete the survey.
Once survey submissions have been processed, the UNC Office of Continuing Professional Development (CPD) will contact eligible participants with next steps for obtaining credit. Please note that CEU requests through the NSGC are no longer being accepted, as the submission deadline has passed.
Credits will be awarded once the CPD office completes its upload process.
MPS Masterclass Virtual Zoom Webinar Agenda
For additional learning, please visit:
2025 MPS MasterClass Video Library
Session 1: November 13, 2025 Recordings : Watch All Videos to Earn Credit for Session 1.
Accreditation Statement
The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Statement
The School of Medicine of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure statement
Planning Committee
This activity has been planned and implemented under the sole supervision of the Course Directors, assisted by the Planning Committee, in association with the UNC Office of Continuing Professional Development (CPD).
Lindsay Torrice (co-course director) and CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.
Ryan Dant was an employee of Grace Science until September 2024. This financial relationship has been mitigated.
Elizabeth Jalazo received consulting fees from Denali, Ionis, JCR, Roche, and Sanofi and research support from Denali, Ionic, JCR, Roche.
Joseph Muenzer (course director) received consulting fees from Applied Therapeutics, Denali, JCR, Regenxbio, Sanofi, and Takeda, and research support from Denali and Takeda.
Dr. Stephens received consulting fees from Denali and Ultragenyx and research support from Takeda.
These financial relationships have been mitigated; Dr. Jalazo, Dr. Muenzer, and Dr. Stephens have recused themselves from planning content related to the products or services offered by the ineligible companies with which they have financial relationships.
Presenters Elizabeth Braunlin, Scott Elton, Jan Fan, David Molter, Marianne Muhlebach, Janey Phelps, and Jennifer Sullivan have no relevant financial relationships with ineligible companies as defined by the ACCME.
Barbara Burton received speaker fees from Alexion, Biomarin, Chiesi, Sanofi, Zevra; consulting fees from Alltrna, Aro, Applied Therapeutics, Biomarin, Denali, JCR Pharma, Moderna, Orchard Therapeutics, Passage Bio, PTC Therapeutics, Sanofi, Takeda, Travere, Ultragenyx, Uniqure; and research grants from Biomarin, Denali, Homology Medicines, JCR Pharma, Moderna, Sangamo, Takeda, Ultragenyx.
Julie Eisengart received consulting fees from Denali, JCR, Novel Pharma, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Sumitomo Pharma Co., Ltd, and Takeda and speaker fees from Takeda.
Mays El-Dairi is a site PI for Viridian.
Jason Madison is a patient consultant for Denali and Lumanity.
Joseph Muenzer – see above.
Paul Orchard received consulting fees from Ionis and research support from Bluebirdbio and Orchard Therapeutics.
Kimberly Stephens – see above.
Lindsay Torrice received consulting fees from Denali (ended August 2025).
Klane White received consulting fees from Biomarin and QED/BridgeBio and research support from Ascendis, QED/BridgeBio, and Ultragenyx.
Tim Wood holds stocks in Biomarin.
These financial relationships have been mitigated through slide review by UNC CPD.
The other presenters listed on the agenda have no relevant financial relationships with ineligible companies as defined by the ACCME.
Commercial Support
This activity did not receive any funding from ineligible companies as defined by the ACCME.
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Session 2: November 14, 2025 Recordings: Watch All Videos to Earn Credit for Session 2.
Accreditation Statement
The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Statement
The School of Medicine of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 15.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure statement
Planning Committee
This activity has been planned and implemented under the sole supervision of the Course Directors, assisted by the Planning Committee, in association with the UNC Office of Continuing Professional Development (CPD).
Lindsay Torrice (co-course director) and CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.
Ryan Dant was an employee of Grace Science until September 2024. This financial relationship has been mitigated.
Elizabeth Jalazo received consulting fees from Denali, Ionis, JCR, Roche, and Sanofi and research support from Denali, Ionic, JCR, Roche.
Joseph Muenzer (course director) received consulting fees from Applied Therapeutics, Denali, JCR, Regenxbio, Sanofi, and Takeda, and research support from Denali and Takeda.
Dr. Stephens received consulting fees from Denali and Ultragenyx and research support from Takeda.
These financial relationships have been mitigated; Dr. Jalazo, Dr. Muenzer, and Dr. Stephens have recused themselves from planning content related to the products or services offered by the ineligible companies with which they have financial relationships.
Presenters Elizabeth Braunlin, Scott Elton, Jan Fan, David Molter, Marianne Muhlebach, Janey Phelps, and Jennifer Sullivan have no relevant financial relationships with ineligible companies as defined by the ACCME.
Barbara Burton received speaker fees from Alexion, Biomarin, Chiesi, Sanofi, Zevra; consulting fees from Alltrna, Aro, Applied Therapeutics, Biomarin, Denali, JCR Pharma, Moderna, Orchard Therapeutics, Passage Bio, PTC Therapeutics, Sanofi, Takeda, Travere, Ultragenyx, Uniqure; and research grants from Biomarin, Denali, Homology Medicines, JCR Pharma, Moderna, Sangamo, Takeda, Ultragenyx.
Julie Eisengart received consulting fees from Denali, JCR, Novel Pharma, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Sumitomo Pharma Co., Ltd, and Takeda and speaker fees from Takeda.
Mays El-Dairi is a site PI for Viridian.
Jason Madison is a patient consultant for Denali and Lumanity.
Joseph Muenzer – see above.
Paul Orchard received consulting fees from Ionis and research support from Bluebirdbio and Orchard Therapeutics.
Kimberly Stephens – see above.
Lindsay Torrice received consulting fees from Denali (ended August 2025).
Klane White received consulting fees from Biomarin and QED/BridgeBio and research support from Ascendis, QED/BridgeBio, and Ultragenyx.
Tim Wood holds stocks in Biomarin.
These financial relationships have been mitigated through slide review by UNC CPD.
The other presenters listed on the agenda have no relevant financial relationships with ineligible companies as defined by the ACCME.
Commercial Support
This activity did not receive any funding from ineligible companies as defined by the ACCME.
 |
 |
 |
 |
 |
 |
 |
 |
|
|
 |
 |
 |
|